IART240920C17500
- 0.96
- -0.34-26.15%
Integra Lifesciences Newsroom
Wells Fargo Downgrades Integra Lifesciences(IART.US) to Hold Rating, Cuts Target Price to $25
Integra Lifesciences: Hold Rating Amidst Compliance Challenges and Revenue Impact With a Long-Term Recovery Outlook
BTIG Maintains Integra Lifesciences(IART.US) With Sell Rating, Maintains Target Price $20
BTIG Sticks to Their Sell Rating for Integra Lifesciences (IART)
BTIG Maintains Integra Lifesciences(IART.US) With Sell Rating, Cuts Target Price to $20
Integra Lifesciences Analyst Ratings
Citi Maintains Integra Lifesciences(IART.US) With Sell Rating, Cuts Target Price to $20
Morgan Stanley Maintains Integra Lifesciences(IART.US) With Sell Rating, Cuts Target Price to $25
A Quick Look at Today's Ratings for Integra Lifesciences(IART.US), With a Forecast Between $22 to $35
Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $26
Integra Lifesciences (IART) Receives a Sell From Morgan Stanley
Truist Financial Reaffirms Their Hold Rating on Integra Lifesciences (IART)
Integra LifeSciences Price Target Announced at $22.00/Share by BTIG
Integra Lifesciences Analyst Ratings
BTIG Downgrades Integra Lifesciences to Sell, Announces $22 Price Target
Truist Adjusts Price Target on Integra LifeSciences Holdings to $26 From $32 After 'Big' H2 Guide Cut, Maintains Hold Rating
Integra Lifesciences Downgraded to Sell on Revised Guidance and Compliance Concerns
Buy Rating Affirmed for Integra Lifesciences Amidst Growth and Recovery Potential
Integra Lifesciences: Strategic Manufacturing Shifts Amid Supply Constraints – A Hold Rating Perspective
Truist Raises Price Target on Integra LifeSciences Holdings to $32 From $25, Maintains Hold Rating